Relafen 750, pharmacologically known as naproxen, represents a noteworthy case study from a pharmacological pharmacy standpoint. This exhibits its pain-relieving effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin production . The targeted inhibition of COX-2, compared to o